[1] |
.RAMAKRISHNAN V,KIMLINGER T,HAUG J,et al.TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells[J]. Am J Hematol,2010,85(9):675-686.
|
[2] |
.张之南,沈悌. 血液病诊断及疗效标准[M]. 3版. 北京:科学出版社,2007:232-235.
|
[3] |
.汪薇. 多发性骨髓瘤实验室检查特点[J]. 检验医学,2015,30(8):847-851.
|
[4] |
.LIN P,OWENS R,TRICOT G,et al.Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma[J]. Am J Clin Pathol,2004,121(4):482-488.
|
[5] |
.RAWSTRON A C,ORFAO A,BEKSAC M,et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders[J]. Haematologica,2008,93(3):431-438.
|
[6] |
.KOBAYASHI S,HYO R,AMITANI Y,et al.Four-color flow cytometric analysis of myeloma plasma cells[J]. Am J Clin Pathol,2006,126(6):908-915.
|
[7] |
.WOJCIECH G.Flow cytometry in neoplastic hematology morphologic-immunophenotypic correlation[M]. 2nd ed. New York:Informa Healthcare,2012:230-237.
|
[8] |
.FLORES-MONTERO J,DE TUTE R,PAIVA B,et al.Immunophenotype of normal vs. myeloma plasma cells:toward antibody panel specifications for MRD detection in multiple myeloma[J]. Cytometry B Clin Cytom,2016,90(1):61-72.
|
[9] |
.MATEO G,MONTALBáN M A,VIDRIALES M B,et al. Prognostic value of immunophenotyping in multiple myeloma:a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy[J]. J Clin Oncol,2008,26(16):2737-2744.
|
[10] |
.郭娟,常春康,苏基滢,等. 应用流式细胞术评估多发性骨髓瘤预后的研究进展[J]. 中国实验血液学杂志,2014,22(4):1178-1182.
|
[11] |
.OTSUYAMA K,ASAOKU H,KAWANO M M.An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis:the revised phenotypic classification of monoclonal marrow plasmacytosis(MOMP-2005)[J]. Int J Hematol,2006,83(1):39-43.
|
[12] |
.MOREAU P,ROBILLARD N,AVET-LOISEAU H,et al.Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma[J]. Haematologica,2004,89(5):547-551.
|
[13] |
.刘莉. 116例多发性骨髓瘤免疫特征表型分析[J]. 检验医学与临床,2013,10(10):1249-1250.
|
[14] |
.JOSHUA D,PETERSEN A,BROWN R,et al.The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis[J]. Br J Haematol,1996,94(1):76-81.
|
[15] |
.KUMAR S,RAJKUMAR S V,KIMLINGER T,et al.CD45 expression by bone marrow plasma cells in multiple myeloma:clinical and biological correlations[J]. Leukemia,2005,19(8):1466-1470.
|
[16] |
.欧阳涓,李俊勋,刘茵,等. 浆细胞CD45和CD31的表达与多发性骨髓瘤细胞分化程度的关系[J]. 中国病理生理杂志,2011,27(2):288-292.
|
[17] |
.CHAN K T,CHOI M Y,LAI K K,et al.Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma[J]. Oncol Rep,2014,31(3):1296-1304.
|
[18] |
.SMITH D,STEPHENSON C,PERCY L,et al.Cohort analysis of FISH testing of CD138(+) cells in relapsed multiple myeloma: implications for prognosis and choice of therapy[J]. Br J Haematol,2015,171(5):881-883.
|